

## INDICE

Acknowledgments	VI
Acronyms and Abbreviations	VII
Users' Guide and Explanatory Notes	VIII
Foreword	XI
Executive Summary	XII
Introduction	1
<b>Section I: Global Malaria Situation</b>	
<b>I. Data Availability and Sources</b>	5
1. Countries with malaria	5
2. WHO annual malaria reporting	6
3. Reported cases and deaths from health information Systems	6
4. Monitoring antimalarial drug efficacy	7
5. Coverage of interventions through household surveys	8
6. Malaria – related commodities and service delivery	9
7. Finances	9
8. Presentation of results	10
<b>II. Malaria Burden</b>	11
<b>III. Malaria Control Policies and Strategies</b>	14
1. Treatment policies	14
2. Insecticide – treated nets	15
3. Indoor residual spraying and other methods of vector control	16
4. Malaria control during epidemics and complex emergencies	16
5. Malaria prevention and treatment in pregnant women	17
<b>Section II: Malaria Control, by Region</b>	
<b>I. Africa</b>	
1. Disease burden	19
2. Control efforts and progress towards Abuja coverage targets	22
3. Coverage of mosquito nets and insecticide – treated nets	22
4. Coverage of antimalarial treatment	31
5. Malaria prevention and treatment in pregnant women	34
6. Coverage of Indoor residual spraying	36
7. Coverage of epidemic detection and control	36
8. Drug efficacy	36
9. Malaria and HIV/AIDS	39
<b>II. Asia</b>	
1. Disease burden and control efforts in:	
* Eastern Mediterranean	40
* Central Asia and Transcaucasia	43
* South – East Asia	45
* Western Pacific	50
2. Age/sex distribution of reported cases	53
3. Coverage of mosquito nets and insecticide – treated nets	56
4. Drug efficacy	57
<b>III. The Americas</b>	
1. Disease burden	59
2. Control efforts	61
3. Drug efficacy	61

<b>Section III: Gloabl Financing, Commodities and Service Delivery</b>	
<b>I. Financing</b>	65
1. Sources of nacional Financing	65
2. The global fund to fight AIDS, tuberculosis and Malaria	67
<b>II. Commodities and Service Delivery</b>	68
1. Net sales and (re-)treatments	68
2. Insecticides used for vector control	69
3. Drug supplies	71
4. Development of new drugs, diagnostics, insecticidas and vaccines	72
<b>Section IV: Improving Roll Back Malaria Monitoring and Evaluation – The Way Forward</b>	
1. Overview of roll back Malria monitoring and evaluation	75
2. Key roll back Malraia coverage and impact indicators, by reion	76
3. Recent progress in monitoring	77
4. Limitations in available data and recommended improvements	80
<b>Referentes</b>	85
<b>Annex 1: Selected Country Profiles</b>	91
<b>Annex 2: Country data, by Region</b>	91
Regional and subregional classification of countries and territorios	213
Explanatory notes for regional tabulations	214
(Regional tabulations are numbered from table A. 1 to Table A. 22)	
<b>Annex 3: Maps</b>	
1. Global distribution of malaria transmisión risk, 2003	281
2. Global distribution of dominant malaria vectors, 2003	282
3. Estimated incidente of clinacal malaria episodes – caused by any species – resulting from local transmisión, country level averages, 2004	283
4. Estimated incidente of clinical P. falciparum episodes resulting from local transmisión, country level averages, 2004	284
5. Drug resistente to P. falciparum from Studies in centinela sites, up to 2004	285
6. Countries that incluye artemisinni – base combination therapy in antimalarial treatment policy, as of 2004	286
<b>Annex 4: The Roll Back Malaria Monitoring and Evaluation Reference Group</b>	
Mortality Task Force	287
Morbidity task Force	288
Malaria – related Anaemia Task Force	289
Survey and indicador guidance task Force	289
Strengthening Country Capacity for Monitoring and Evaluation task force	290
<b>Aneex 5: Definitions</b>	
WHO standard malaria case definitions	291
Other definitions	292
<b>Annex 6: RBM and Who Guidelines on Malaria Control</b>	293